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Patients with advanced Hodgkin disease (HD) who have arelapse after first-line chemotherapy can achieve furtherremissions with high-dose chemotherapy and transplan-tation of hematopoietic stem cells. Unfortunately, re-
lapse or disease progression after autologous transplant occurs in a
significant proportion of cases, and no clear treatment guidelines
exist for these patients. We report the case of a patient with a
refractory localized HD who had a sustained long-term remission
(39 months) after surgery alone.
Clinical Summary
A 22-year-old male student was seen in November 1995 with B
signs and superior vena cava syndrome. HD of the nodular scle-
rosis type was diagnosed at stage IIIB with bulky mediastinum.
The patient was treated with 6 cycles of doxorubicin, bleomycin,
vinblastine, and dacarbazine to achieve a complete remission,
consolidated by 40-Gy radiotherapy to initial sites of bulky medi-
astinum and by 30-Gy radiotherapy to neck and axillary areas.
Two years after completion of therapy, the disease recurred as a
localized left lung suprahilar nodule within the previously irradi-
ated field. The patient was successfully treated with 3 courses of
etoposide, vinblastine, cytarabine, and cisplatin chemotherapy,
followed by high-dose chemotherapy (carmustine, etoposide, cyt-
arabine, and melphalan) and autologous hematopoietic stem cell
transplantation in December 1998. The disease recurred at the
same location in November 1999. The patient was treated with 4
cycles of standard bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine, and prednisone therapy, with
complete remission. However, this discrete lesion reappeared in
February 2001. Because this localized HD was not sensitive to
chemotherapy and complementary irradiation was excluded be-
cause of location at the margin of the previously irradiated field, a
surgical approach was elected. The patient underwent a left upper
pulmonary lobectomy with radical mediastinal lymph node dissec-
tion in March 2001. The pathologic examination confirmed the
presence of a discrete, well-defined lesion showing the histologic
characteristics of HD of the nodular sclerosis subgroup, without
lymph node dissemination. Complete remission persists as of May
2004, with negative results of fluorodeoxyglucose positron emis-
sion tomographic scan and no evidence of recurrence on chest
computed tomography.
Discussion
Patients with advanced HD that relapses after first-line chemother-
apy may have further remissions with salvage treatment. High-
dose chemotherapy and transplantation of hematopoietic stem cells
improves freedom from treatment failure in patients with chemo-
sensitive first relapse of HD, irrespective of delay after initial
remission.1-3 Unfortunately, relapse or disease progression after
autologous transplantation occurs in a significant proportion of
patients with HD, and no clear-cut therapeutic guidelines exist for
these patients for whom both first-line and high-dose salvage
regimens have failed.4 Gemcitabine, monoclonal antibodies, and
active immunotherapy may be tested as alternatives to the option
of conventional or nonmyeloablative allogeneic transplantation.3,5
The favorable course observed in our patient suggests that elective
surgery might be an alternative for highly selected patients with
recurrent localized HD, especially pulmonary recurrence.
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